SHIJIAZHUANG, China, July 1, 2020 /PRNewswire/ -- Following Thailand, Singapore and Indonesia, Yiling Pharmaceutical (002603.SZ), a leader in the development of traditional Chinese medicines (TCM), obtained a Certificate of Registration issued by the Drug Department of Laos' Ministry of Health which registers Lianhua Qingwen Capsule as Chinese Proprietary Medicine (CPM).
"The Certificate of Registration issued by the Drug Department of Laos' Ministry of Health grants Lianhua Qingwen sale authorization and registers it as a medical product, which will help the company extend its global footprint," said Zhang Qiulian, the Deputy GM of Yiling Pharmaceutical.
In addition, multiple countries have also held online conference with Chinese medical experts to learn their experience about the adoption and the efficacy of the drug in increasing the recovery rate of COVID-19 patients. On June 17, an academic webinar was hosted by the Ministry of Health of Thailand to introduce the clinical use of Lianhua Qingwen.
During the session, Professor Gao Zhancheng from Peking University People's Hospital, member of the Chinese Medical Association Respiratory Branch, presented an academic report titled "The Prevention and Treatment New Respiratory Virus Infection by Traditional Chinese Medicines." Professor Ding Banghan from the Guangdong Provincial Hospital of Traditional Chinese Medicine, Deputy Chairman of the Committee on Emergency Medical Service of Chinese Society of Integrated Traditional Chinese and Western Medicine, shared theories and practices of preventing and treating infectious respiratory diseases with traditional Chinese medicines.
China's top two medical academicians introduced the latest research results and clinical application of Lianhua Qingwen with Chinese and Western medical practitioners from Thailand VachiraPhuket Hospital, Phra Nang Klao Hospital, Trang Hospital, Luang Por Poen Hospital, Hua Hin Hospital and Hua Chiew Traditional Chinese Medicine Hospital.
Wang Yiliang, Director of the Alternative Medicine Division of the Ministry of Health of Thailand, said that "clinical trials conducted in China have shown that Linahua Qingwen can improve the recovery rate of patients infected with COVID-19. The State Drug Administration of China has recognized its crucial role in containing the pandemic and listed new indications of Lianhua Qingwen in the treatment for mild and common COVID-19 symptoms." By hosting this academic webinar, the Alternative Medicine Division hopes to integrate the knowledge of integrated traditional Chinese and western medicine and its functions in the development of modern medicine into the Thai health service system through in-depth cooperation.
In speaking of the significance of the online academic conference, Wang Yiliang said: "The online conference allowed us to learn the application of Lianhua Qingwen Capsule in the treatment of respiratory diseases including influenza and COVID-19 pneumonia. Lianhua Qingwen has been through rigorous medical research and clinical trial, and it has drawn much attention from Thailand's medical community."
"Safety, effectiveness and quality control are our priorities when it comes to evaluating the feasibility of using traditional medicines for clinical treatment. Lianhua Qingwen has set a good example for us," he said.
The latest approval issued by Lao's Ministry of Health marks another milestone for the drug, which is accepted as one of the first TCM solutions to help tackle the current strain of coronavirus. To date, nine countries including Brazil, Indonesia, Canada, Mozambique and Romania have also granted marketing and sale authorization to Lianhua Qingwen.